COMP <GO>
NNNN vs MYGN // EV/EBITDA & P/E VALUATION
Anbio Biotechnology (Class A) (NASDAQ) VS. Myriad Genetics Inc. (NASDAQ) • 15-METRIC TALLY: NNNN 5
— MYGN 4
■ METRIC PARITY
LAST: $3.72 (-3.12%) • MKT CAP: $535.3M
valuation
91.5x
LAST: $6.67 (+0.60%) • MKT CAP: $638.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. MYGN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | MYGN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 69.90% | +17.30 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | -35.00% | +52.00 | NNNN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 91.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | 0.28% | -1.54 | MYGN | /fcf-yield <GO> |
| Operating Margin | 66.70% | -47.00% | +113.70 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -44.40% | +112.40 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | -1.60% | +7.20 | NNNN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | MYGN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.4 | 72.7 | -43.22 | MYGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 77.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $638.0M | -$102.7M | MYGN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | MYGN REV | NNNN GROSS % | MYGN GROSS % | NNNN FCF | MYGN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $824.5M | 87.2% | 69.9% | -$6.7M | $1.8M |
| FY 2024 | $8.2M | $837.6M | 71.9% | 69.9% | $2.1M | -$8.7M |
| FY 2023 | $6.7M | $753.2M | — | — | $898.4K | -$110.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
MYGN // BETA —